AAAAAA
Results: 1-25/62
Authors:
VIERBOOM MPM
FELTKAMP MCW
NEISIG A
DRIJFHOUT JW
TERSCHEGGET J
NEEFJES JJ
MELIEF CJM
KAST WM
Citation: Mpm. Vierboom et al., PEPTIDE VACCINATION WITH AN ANCHOR-REPLACED CTL EPITOPE PROTECTS AGAINST HUMAN-PAPILLOMAVIRUS TYPE 16-INDUCED TUMORS EXPRESSING THE WILD-TYPE EPITOPE, Journal of immunotherapy, 21(6), 1998, pp. 399-408
Authors:
AGEITOS AG
SINGH RK
INO K
OZEROL I
TARANTOLO S
REED EK
TALMADGE JE
Citation: Ag. Ageitos et al., IL-2 EXPANSION OF T-CELL AND NK-CELL FROM GROWTH FACTOR-MOBILIZED PERIPHERAL-BLOOD STEM-CELL PRODUCTS - MONOCYTE INHIBITION, Journal of immunotherapy, 21(6), 1998, pp. 409-417
Authors:
RASMUSSEN MV
SILBART LK
Citation: Mv. Rasmussen et Lk. Silbart, PERORAL ADMINISTRATION OF SPECIFIC ANTIBODY ENHANCES CARCINOGEN EXCRETION, Journal of immunotherapy, 21(6), 1998, pp. 418-426
Authors:
BROUWENSTIJN N
HOOGSTRATEN C
VERDEGAAL EME
VANDERSPEK CW
DECKERS JG
MULDER S
OSANTO S
SCHRIER PI
Citation: N. Brouwenstijn et al., DEFINITION OF UNIQUE AND SHARED T-CELL DEFINED TUMOR-ANTIGENS IN HUMAN RENAL-CELL CARCINOMA, Journal of immunotherapy, 21(6), 1998, pp. 427-434
Authors:
LOMBARDI ML
MERCURO O
PIROZZI G
IONNA F
LOMBARI V
MOZZILLO N
MANZO C
Citation: Ml. Lombardi et al., MOLECULAR ANALYSIS OF HLA DRB1 AND DQB1 POLYMORPHISM IN ITALIAN MELANOMA PATIENTS, Journal of immunotherapy, 21(6), 1998, pp. 435-439
Authors:
WHITEHEAD RP
UNGER JM
GOODWIN JW
WALKER MJ
THOMPSON JA
FLAHERTY LE
SONDAK VK
Citation: Rp. Whitehead et al., PHASE-II TRIAL OF RECOMBINANT HUMAN INTERLEUKIN-4 IN PATIENTS WITH DISSEMINATED MALIGNANT-MELANOMA - A SOUTHWEST-ONCOLOGY-GROUP STUDY, Journal of immunotherapy, 21(6), 1998, pp. 440-446
Authors:
OR R
ACKERSTEIN A
NAGLER A
AMAR A
NAPARSTEK E
VARADI G
KAPELUSHNIK J
SAMUEL S
PUGATSCH T
BRAUTBAR C
SLAVIN S
Citation: R. Or et al., ALLOGENEIC CELL-MEDIATED AND CYTOKINE-ACTIVATED IMMUNOTHERAPY FOR MALIGNANT-LYMPHOMA AT THE STAGE OF MINIMAL RESIDUAL DISEASE AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION, Journal of immunotherapy, 21(6), 1998, pp. 447-453
Citation: 13TH ANNUAL-MEETING OF THE SOCIETY-FOR-BIOLOGICAL-THERAPY - OCTOBER 21-24, 1998 PITTSBURGH, PENNSYLVANIA - ABSTRACTS, Journal of immunotherapy, 21(6), 1998, pp. 454-467
Authors:
FIELDS RC
OSTERHOLZER JJ
FULLER JA
THOMAS EK
GERAGHTY PJ
MULE JJ
Citation: Rc. Fields et al., COMPARATIVE-ANALYSIS OF MURINE DENDRITIC CELLS DERIVED FROM SPLEEN AND BONE-MARROW, Journal of immunotherapy, 21(5), 1998, pp. 323-339
Authors:
EUE I
KUMAR R
DONG YY
KILLION JJ
FIDLER IJ
Citation: I. Eue et al., INDUCTION OF NITRIC-OXIDE PRODUCTION AND TUMORICIDAL PROPERTIES IN MURINE MACROPHAGES BY A NEW SYNTHETIC LIPOPEPTIDE JBT3002 ENCAPSULATED IN LIPOSOMES, Journal of immunotherapy, 21(5), 1998, pp. 340-351
Authors:
NISHIMURA MI
CUSTER MC
SCHWARZ SL
PARKER LL
MIXON A
CLAY TM
YANNELLI JR
ROSENBERG SA
Citation: Mi. Nishimura et al., T-CELL-RECEPTOR-V GENE USE BY CD4(-REACTIVE CLONAL AND OLIGOCLONAL T-CELL LINES() MELANOMA), Journal of immunotherapy, 21(5), 1998, pp. 352-362
Authors:
ALATRAKCHI N
FARACE F
FRAU E
CARDE P
MUNCK JN
TRIEBEL F
Citation: N. Alatrakchi et al., T-CELL CLONAL EXPANSION IN PATIENTS WITH B-CELL LYMPHOPROLIFERATIVE DISORDERS, Journal of immunotherapy, 21(5), 1998, pp. 363-370
Authors:
ROSENTHAL MA
DENNIS D
LIEBES L
FURMANSKI P
CARON D
GARRISON L
WIPROVNICK J
PEACE D
ORATZ R
SPEYER J
CHACHOUA A
Citation: Ma. Rosenthal et al., BIOLOGIC ACTIVITY OF INTERLEUKIN-1 (IL-1)ALPHA IN PATIENTS WITH REFRACTORY MALIGNANCIES, Journal of immunotherapy, 21(5), 1998, pp. 371-378
Authors:
SALEH MN
LALISAN DY
PRIDE MW
SOLINGER A
MAYO MS
LOBUGLIO AF
MURRAY JL
Citation: Mn. Saleh et al., IMMUNOLOGICAL RESPONSE TO THE DUAL MURINE ANTI-ID VACCINE MELIMMUNE-1AND MELIMMUNE-2 IN PATIENTS WITH HIGH-RISK MELANOMA WITHOUT EVIDENCE OF SYSTEMIC-DISEASE, Journal of immunotherapy, 21(5), 1998, pp. 379-388
Authors:
DAVIDSON JA
MUSK AW
WOOD BR
MOREY S
ILTON M
YU LL
DRURY P
SHILKIN K
ROBINSON BWS
Citation: Ja. Davidson et al., INTRALESIONAL CYTOKINE THERAPY IN CANCER - A PILOT-STUDY OF GM-CSF INFUSION IN MESOTHELIOMA, Journal of immunotherapy, 21(5), 1998, pp. 389-398
Authors:
KAWAKAMI Y
ROBBINS PF
WANG RF
PARKHURST M
KANG XQ
ROSENBERG SA
Citation: Y. Kawakami et al., THE USE OF MELANOSOMAL PROTEINS IN THE IMMUNOTHERAPY OF MELANOMA, Journal of immunotherapy, 21(4), 1998, pp. 237-246
Authors:
HENDERSON RA
KONITSKY WM
BARRATTBOYES SM
SOARES M
ROBBINS PD
FINN OJ
Citation: Ra. Henderson et al., RETROVIRAL EXPRESSION OF MUC-1 HUMAN TUMOR-ANTIGEN WITH INTACT REPEATSTRUCTURE AND CAPACITY TO ELICIT IMMUNITY IN-VIVO, Journal of immunotherapy, 21(4), 1998, pp. 247-256
Authors:
CHEN W
QIN HL
REESE VA
CHEEVER MA
Citation: W. Chen et al., CTLS SPECIFIC FOR BCR-ABL JOINING REGION SEGMENT PEPTIDES FAIL TO LYSE LEUKEMIA-CELLS EXPRESSING P210 BCR-ABL PROTEIN, Journal of immunotherapy, 21(4), 1998, pp. 257-268
Authors:
JANETZKI S
BLACHERE NE
SRIVASTAVA PK
Citation: S. Janetzki et al., GENERATION OF TUMOR-SPECIFIC CYTOTOXIC T-LYMPHOCYTES AND MEMORY T-CELLS BY IMMUNIZATION WITH TUMOR-DERIVED HEAT-SHOCK-PROTEIN GP96, Journal of immunotherapy, 21(4), 1998, pp. 269-276
Authors:
DUBEY P
MEREDITH SC
SIEGEL CT
SCHREIBER H
Citation: P. Dubey et al., TUMOR-CELLS INDUCE CYTOLYTIC T-CELLS TO A SINGLE IMMUNODOMINANT MUTANT PEPTIDE, Journal of immunotherapy, 21(4), 1998, pp. 277-282
Authors:
LONE YC
MOTTA I
MOTTEZ E
GUILLOUX Y
LIM A
DEMAY F
LEVRAUD JP
KOURILSKY P
ABASTADO JP
Citation: Yc. Lone et al., IN-VITRO INDUCTION OF SPECIFIC CYTOTOXIC T-LYMPHOCYTES USING RECOMBINANT SINGLE-CHAIN MHC CLASS-I PEPTIDE COMPLEXES, Journal of immunotherapy, 21(4), 1998, pp. 283-294
Authors:
REICHERT TE
RABINOWICH H
JOHNSON JT
WHITESIDE TL
Citation: Te. Reichert et al., MECHANISMS RESPONSIBLE FOR SIGNALING AND FUNCTIONAL DEFECTS, Journal of immunotherapy, 21(4), 1998, pp. 295-306
Authors:
FLOOD PM
LIU XM
ALEXANDER R
SCHREIBER H
HAQUE S
Citation: Pm. Flood et al., LOSS OF RESISTANCE TO A HIGHLY IMMUNOGENIC TUMOR WITH AGE CORRESPONDSTO THE DECLINE OF CD8 T-CELL ACTIVITY, Journal of immunotherapy, 21(4), 1998, pp. 307-316
Authors:
NIELAND JD
LOVISCEK K
KONO K
ALBAIN KS
MCCALL AR
POTKUL RK
FISHER SG
VELDERS MP
PETERSSON M
KIESSLING T
KAST WM
Citation: Jd. Nieland et al., PBLS OF EARLY BREAST-CARCINOMA PATIENTS WITH A HIGH NUCLEAR GRADE TUMOR UNLIKE PBLS OF CERVICAL-CARCINOMA PATIENTS DO NOT SHOW A DECREASED TCR-ZETA EXPRESSION BUT ARE FUNCTIONALLY IMPAIRED, Journal of immunotherapy, 21(4), 1998, pp. 317-322
Authors:
BEI R
GUPTILL V
MASUELLI L
KASHMIRI SVS
MURARO R
FRATI L
SCHLOM J
KANTOR J
Citation: R. Bei et al., THE USE OF A CATIONIC LIPOSOME FORMULATION (DOTAP) MIXED WITH A RECOMBINANT TUMOR-ASSOCIATED ANTIGEN TO INDUCE IMMUNE-RESPONSES AND PROTECTIVE IMMUNITY IN MICE, Journal of immunotherapy, 21(3), 1998, pp. 159-169